看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -3.5x - -3.9x | -3.7x |
| Selected Fwd P/E Multiple | -5.6x - -6.1x | -5.9x |
| Fair Value | $2.66 - $2.94 | $2.80 |
| Upside | 26.2% - 39.5% | 32.8% |
| Benchmarks | - | Full Ticker |
| Agilent Technologies, Inc. | - | NYSE:A |
| AbCellera Biologics Inc. | - | NasdaqGS:ABCL |
| WuXi Biologics (Cayman) Inc. | - | OTCPK:WXIB.F |
| Lonza Group AG | - | OTCPK:LZAG.F |
| Bristol-Myers Squibb Company | - | NYSE:BMY |
| Codexis, Inc. | - | NasdaqGS:CDXS |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| A | ABCL | WXIB.F | LZAG.F | BMY | CDXS | |||
| NYSE:A | NasdaqGS:ABCL | OTCPK:WXIB.F | OTCPK:LZAG.F | NYSE:BMY | NasdaqGS:CDXS | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 3.8% | NM- | 27.1% | -0.3% | NM- | NM- | ||
| 3Y CAGR | 2.1% | NM- | -0.3% | -1.9% | NM- | NM- | ||
| Latest Twelve Months | 1.9% | -11.2% | -1.3% | -2.8% | -211.5% | 14.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 17.6% | -115.3% | 27.8% | 23.5% | 1.1% | -51.1% | ||
| Prior Fiscal Year | 18.1% | -385.0% | 20.0% | 9.7% | 17.8% | -108.7% | ||
| Latest Fiscal Year | 19.8% | -564.8% | 18.0% | 9.7% | -18.5% | -110.0% | ||
| Latest Twelve Months | 19.3% | -564.8% | 18.0% | 9.7% | -18.5% | -110.0% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 17.4x | -0.4x | 13.2x | 23.2x | 7.1x | -3.0x | ||
| Price / LTM Sales | 4.5x | 25.0x | 4.2x | 5.8x | 2.1x | 3.0x | ||
| LTM P/E Ratio | 23.3x | -4.4x | 23.3x | 59.5x | -11.2x | -2.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -11.2x | 23.3x | 59.5x | |||||
| Historical LTM P/E Ratio | -135.2x | -9.8x | -2.6x | |||||
| Selected P/E Multiple | -3.5x | -3.7x | -3.9x | |||||
| (x) LTM Net Income | (65) | (65) | (65) | |||||
| (=) Equity Value | 230 | 242 | 254 | |||||
| (/) Shares Outstanding | 82.8 | 82.8 | 82.8 | |||||
| Implied Value Range | 2.78 | 2.92 | 3.07 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2.78 | 2.92 | 3.07 | 2.11 | ||||
| Upside / (Downside) | 31.7% | 38.6% | 45.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A | ABCL | WXIB.F | LZAG.F | BMY | CDXS | |
| Value of Common Equity | 29,217 | 721 | 80,992 | 39,252 | 100,171 | 175 | |
| (/) Shares Outstanding | 285.1 | 298.0 | 4,047.8 | 70.6 | 2,034.8 | 82.8 | |
| Implied Stock Price | 102.48 | 2.42 | 20.01 | 555.69 | 49.23 | 2.11 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 7.30 | 0.82 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 102.48 | 2.42 | 2.74 | 678.67 | 49.23 | 2.11 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 7.30 | 0.82 | 1.00 | 1.00 | |